Lysoveta Trials And Houston Restructuring Will Expand Omega-3 Reach

Published
09 Feb 25
Updated
21 Aug 25
AnalystConsensusTarget's Fair Value
NOK 61.96
33.0% overvalued intrinsic discount
21 Aug
NOK 82.40
Loading
1Y
-17.4%
7D
1.9%

Author's Valuation

NOK 62.0

33.0% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 11%

Shared on23 Apr 25
Fair value Decreased 12%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on17 Apr 25
Fair value Increased 1.83%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 18%

Shared on02 Apr 25
Fair value Decreased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 1.29%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 8.05%

AnalystConsensusTarget has decreased revenue growth from 14.5% to 10.9%, decreased profit margin from 12.6% to 10.0%, increased future PE multiple from 12.4x to 22.2x and increased shares outstanding growth rate from -0.1% to 0.0%.